Maze Therapeutics Chief Medical Officer Sells 15K Shares As Company's Stock Continues to Surge

Maze Therapeutics has been flourishing as a stock and in its operations, which is one of the reasons its Chief Medical Officer's recent share sale shouldn't raise concerns for investors. On Feb. 2, 2026, Harold Bernstein, President, R&D & CMO of Maze Therapeutics (MAZE 2.04%), exercised 15,000 options and immediately sold the resulting shares in an open-market transaction, fully divesting his direct ownership, according to a SEC Form 4 filing. Transaction summaryMetricValueShares sold (direct)15,000Transact ...